Abstract
Background: GIST are the most common mesenchymal tumours of the GI tract and in GI tract it arises most commonly from stomach followed by small intestine. Mostly GIST is asymptomatic and their presentation depends upon their site and size. Symptomatic patients present with anaemia, GI bleeding, abdominal pain and obstruction. Complete resection is standard and curative. Tyrosine kinase receptors are useful in management of high risk GISTs, advanced, recurrent and metastatic tumours.
Aim: The aim of this study is to analyse the clinical data of GIST patients who presented with acute symptoms.
Material and Methods: The clinical data of GIST patient who presented between Jan 2013 to Mar 2018 along with their clinical presentations, radiological and endoscopic data, surgical procedures, follow up data were collected and analysed.
Results: 23 patients (13 males and 10 females) presented with acute symptoms who were diagnosed to have GIST. The GIST was located in stomach in 10 patients, in small intestine in 10 patients, in colon in 1 patients and in rectum in 2 patients. Pain abdomen and GI bleeding were the most common symptoms followed by intestinal obstruction. All 23 patients underwent surgical exploration. Complete macroscopic resection was achieved in 21 patients, while 2 patients had palliative and incomplete resection. Two patients with small intestine GIST developed recurrence/ metastases. One patient had mortality on 2 years follow-up.
Conclusion: GISTs are uncommon tumours and few of GISTs presents with acute symptoms. The patients with chronic anaemia and recurrent abdominal pain need evaluation and work up for GIST. Surgery remains the gold standard treatment in localized GIST. Large GISTs may require Neo-adjuvant chemotherapy to increase resectability of tumour. Anatomical site of primary tumour, size of tumour, completeness of surgical resection, tumour pseudo capsule rupture and response to chemotherapy affects the prognosis and recurrence. Early resuscitation, diagnosis and surgical treatment affects the outcome in GIST related emergencies.
Keywords: Gastrointestinal Stromal Tumours, Imatinib, Tyrosine Kinase Inhibitors, Intussusception
References
- Kindblom L-G, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cell of Cajal. Am J Pathol1998; 152:1259–1269.
- Soreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies.Cancer Epidemiol. 2015; 40:39-46.
- Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour.Lancet 2013; 382:973–983.
- Fletcher, J.J. Berman, C. Corless, et al., Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathology 33 (2002) 459-465.
- Paolo G. Casali, Angelo Paolo Dei Tos, and Alessandro Gronchi.Gastrointestinal stromal tumors, in: V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.), Cancer: Principles and Practice of Oncology, Lippincott Williams & Wilkins, Philadelphia, 2015, pp. 745-756.
- Zheng S, Chen LR, Wang HJ, Chen SZ. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor. Hepatogastroenterology. 2007;54(80):2285-2290.
- Nishida T, Goto O, Raut CP, Yahagi N. Diagnostic and treatment strategy for small gastrointestinal stromal tumors. Cancer. 2016;122(20):3110-3118.
- B. Amin et al. (eds.), AJCC Cancer Staging Manual, Eighth Edition. Chicago, Springer 2017.
- Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Seminars in diagnostic pathology. May 2006;23(2):70-83.
- Fletcher CD. Clinicopathologic correlations in gastrointestinal stromal tumors. Hum Pathol. 2002;33(5):455.
- Joensuu H. Risk stratifcation of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39(10):1411-1419.
- Hong X, Choi H, Loyer EM, Benjamin RS, Trent JC, Charnsangavej C. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib.Radiographics. 2006;26(2):481-495
- Toshirou Nishida. The Role of Endoscopy in the Diagnosis of Gastric
Gastrointestinal Stromal Tumors. Ann Surg Oncol (2015) 22:2810–2811.
- Nishida T, Goto O, Raut CP, Yahagi N. Diagnostic and treatment strategy for small gastrointestinal stromal tumors.Cancer. 2016;122(20):3110-3118.
- Van den Abbeele AD. The lessons of GIST–PET and PET/CT: a new paradigm for imaging. Oncologist. 2008;13(suppl 2):8-13.
- Miyake KK, Nakamoto Y, Mikami Y, et al. The predictive value of preoperative 18 F-fluorodeoxyglucose PET for postoperative recurrence in patients with localized primary gastrointestinal stromal tumour.Eur Radiol. 2016;26(12):4664-4674.
- Jian-Xin Cui, Yun-He Gao, Hong-Qing Xi, Ai-Zhen Cai et al. Comparison between laparoscopic and open surgery for large gastrointestinal stromal tumors: A meta-analysis. World J Gastrointest Oncol 2018; 10(1): 48-55.
- Ohtani H, Maeda K, Noda E, et al. Meta-analysis of laparoscopic and open surgery for gastric gastrointestinal stromal tumor. Anticancer Res 2013; 33:5031–5041.
- Chen CW, Wu CC, Hsiao CW, et al. Surgical management and clinical outcome of gastrointestinal stromal tumor of the colon and rectum.Z Gastroenterol. 2008;46(8):760-765
- DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51–58.
- McCarter MD, Antonescu CR, Ballman KV, et al. Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. J Am Coll Surg 2012; 215:53–59.
- Demetri GD, von Mehren M, Antonescu CR, et al. NCCN task force report: update on the management of patients with gastrointestinal stromal tumors.J Natl ComprCancNetw. 2010;8(suppl 2): S1-S41.
- Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.N Engl J Med. 2001;344(14):1052-1056.
- DeMatteo RP, Ballman KV, Antonescu CR, et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg. 2013;258(3):422-428.
- Joensuu H, Eriksson M, Sundby Hall K, et al. Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial.J Clin Oncol. 2016;34(3):244-250.
- Reichardt.Practical aspects of managing gastrointestinal stromal tumors. Monographs in Gastrointestinal Stromal Tumors 1 (2003) 3-8.
- C. Lin, M.J. Huang, C.Y. Zeng, et al. Clinical manifestations and prognostic
factors in patients with gastrointestinal stromal tumors. World Journal of Gastroenterology 9 (2003) 2809-2812.
Corresponding Author
Vijay Chetan Jha
MBBS, MS, MCh (GI Surgery), Command Hospital (EC), Kolkata 700027
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
DOI: https://dx.doi.org/10.18535/jmscr/v6i6.43
